IBI-363 is a PD-1/IL-2 bispecific antibody with the functions of blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. The IL-2 arm of IBI-363 retains affinity for IL-2Ralpha while attenuating its binding capacity to IL-2Rbeta and IL-2Rgamma for toxicity reduction. The PD-1-binding arm of IBI-363 enables PD-1 blockade and the selective delivery of IL-2. IBI-363 can be used for cancer research, such as non-small cell lung cancer[1].
Molekulargewicht:
(112.48 kDa)
Reinheit:
99.60
Target-Kategorie:
Interleukin Related,PD-1/PD-L1
Anwendungsbeschreibung:
MCE Product type: Inhibitory Antibodies
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
